Trial Profile
A Prospective, Multicenter, Randomized, Open-label Trial to Assess the Safety, Tolerability and Efficacy of Dual Therapy With Boosted Darunavir + Dolutegravir When Switching From Standard of Care ART in HIV-patients With Sustained Virological Suppression: The DUALIS Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Darunavir (Primary) ; Dolutegravir (Primary) ; Ritonavir (Primary) ; Emtricitabine/tenofovir alafenamide; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms DUALIS
- 16 Feb 2022 Results of subanalysis assessing changes in metabolic and renal parameters when sparing the Nrti-Free 2 Drug Regimen backbone presented at the 29th Conference on Retroviruses and Opportunistic Infections
- 07 Jul 2020 Results published in the Journal of Antimicrobial Chemotherapy
- 11 Mar 2020 Results of post-hoc analysis of virologic outcomes in DUALIS has been presented at the 27th Conference on Retroviruses and Opportunistic Infections